Schering AG Expects Restructuring Program Will Result In Charges Of $90 Mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
The German pharmaceutical company has cut 600 jobs out of the 2,000 that will be eliminated as part of its portfolio restructuring. Schering AG will spread the charges over 2004 and 2005.
You may also be interested in...
Schering AG Dermatology Business “Intendis” To Begin Operations Jan. 1
The U.S. branch of Intendis will operate out of Montville, N.J. Leadership will include former VP of Schering AG’s U.S. dermatology business Bernhard Schefter as North America marketing head.
Schering AG Making Oncology A Primary Focus; Dermatology Unit Will Become Separate Entity
Berlex’ German parent says the new focus will help it exploit the potential of a Phase III angiogenesis inhibitor under development with Novartis. Portfolio restructuring includes termination of R&D in cardiovascular and CNS areas, except for multiple sclerosis and Parkinson’s disease.
U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.